SG11201506499YA - Low concentration antibody formulations - Google Patents
Low concentration antibody formulationsInfo
- Publication number
- SG11201506499YA SG11201506499YA SG11201506499YA SG11201506499YA SG11201506499YA SG 11201506499Y A SG11201506499Y A SG 11201506499YA SG 11201506499Y A SG11201506499Y A SG 11201506499YA SG 11201506499Y A SG11201506499Y A SG 11201506499YA SG 11201506499Y A SG11201506499Y A SG 11201506499YA
- Authority
- SG
- Singapore
- Prior art keywords
- low concentration
- antibody formulations
- concentration antibody
- formulations
- low
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787709P | 2013-03-15 | 2013-03-15 | |
| PCT/IB2014/059757 WO2014141152A2 (en) | 2013-03-15 | 2014-03-13 | Low concentration antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201506499YA true SG11201506499YA (en) | 2015-09-29 |
Family
ID=50397215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201506499YA SG11201506499YA (en) | 2013-03-15 | 2014-03-13 | Low concentration antibody formulations |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10537638B2 (en) |
| EP (2) | EP2968535A2 (en) |
| JP (1) | JP6541581B2 (en) |
| KR (1) | KR20150132332A (en) |
| CN (1) | CN105073136A (en) |
| AU (1) | AU2014229282B2 (en) |
| BR (1) | BR112015023498A2 (en) |
| CA (1) | CA2902289A1 (en) |
| IL (1) | IL240754A0 (en) |
| RU (1) | RU2015137685A (en) |
| SG (1) | SG11201506499YA (en) |
| TW (1) | TW201501724A (en) |
| WO (1) | WO2014141152A2 (en) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107586340B (en) | 2011-08-23 | 2022-01-21 | 罗切格利卡特公司 | Bispecific antibodies specific for T cell activating antigens and tumor antigens and methods of use |
| EP2904016B1 (en) | 2012-10-08 | 2018-11-14 | Roche Glycart AG | Fc-free antibodies comprising two fab-fragments and methods of use |
| EP3444278A1 (en) | 2013-02-26 | 2019-02-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| CN104936986B (en) | 2013-02-26 | 2019-08-09 | 罗切格利卡特公司 | Bispecific T cell activation antigen binding molecules |
| CN105073136A (en) | 2013-03-15 | 2015-11-18 | 葛兰素史克知识产权第二有限公司 | Low concentration antibody formulations |
| UA120753C2 (en) | 2013-12-17 | 2020-02-10 | Дженентек, Інк. | Anti-cd3 antibodies and methods of use |
| DK3177643T3 (en) | 2014-08-04 | 2019-07-15 | Hoffmann La Roche | Bispecific T cell activating antigen binding molecules |
| AR101846A1 (en) | 2014-09-12 | 2017-01-18 | Genentech Inc | ANTI-CLL-1 ANTIBODIES AND IMMUNOCATE PLAYERS |
| EP4141032B1 (en) | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
| TW201718647A (en) | 2015-06-16 | 2017-06-01 | 建南德克公司 | Anti-CLL-1 antibodies and methods of use |
| WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| CA2986928A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Humanized and affinity matured antibodies to fcrh5 and methods of use |
| AR106188A1 (en) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE |
| MA43025A (en) | 2015-10-02 | 2021-05-26 | Hoffmann La Roche | BISPECIFIC BISPECIFIC MOLECULES OF ANTIGEN ACTIVATING T-LYMPHOCYTES ANTI-CEAXCD3 |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| BR112018003984A2 (en) | 2015-12-09 | 2018-09-25 | Hoffmann La Roche | antibodies |
| SG11201804961UA (en) * | 2015-12-30 | 2018-07-30 | Genentech Inc | Formulations with reduced degradation of polysorbate |
| PL3400246T3 (en) | 2016-01-08 | 2021-03-08 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
| WO2017134306A1 (en) | 2016-02-05 | 2017-08-10 | Orionis Biosciences Nv | Cd8 binding agents |
| DK3433280T3 (en) | 2016-03-22 | 2023-06-19 | Hoffmann La Roche | Protease-activated T-cell bispecific molecules |
| SG11201807402PA (en) | 2016-03-31 | 2018-09-27 | Vhsquared Ltd | Compositions |
| SE540001C2 (en) * | 2016-04-05 | 2018-02-20 | Kyttinge Invest Ab | Self-propelling trolley assembly |
| WO2018060301A1 (en) | 2016-09-30 | 2018-04-05 | F. Hoffmann-La Roche Ag | Bispecific antibodies against cd3 |
| AR109621A1 (en) * | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | FORMULATIONS OF VACCINES AGAINST GLUCOCONJUGADOS OF EXPEC |
| EP3541843A1 (en) | 2016-11-15 | 2019-09-25 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| WO2019040612A1 (en) * | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| MA50266A (en) * | 2017-09-22 | 2020-07-29 | Immunogen Inc | METHODS FOR PREVENTING THE OXIDATION OF METHIONINE IN IMMUNOCONJUGATES |
| WO2019064263A1 (en) * | 2017-09-29 | 2019-04-04 | Janssen Biotech, Inc. | Novel formulations which stabilize low dose antibody compositions |
| CA3089287A1 (en) | 2018-02-08 | 2019-08-15 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
| PE20212185A1 (en) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | FORMULATION OF THERAPEUTIC ANTIBODIES |
| MX2021015761A (en) | 2019-06-21 | 2022-04-18 | Sorriso Pharmaceuticals Inc | Polypeptides. |
| CN114514243A (en) | 2019-06-21 | 2022-05-17 | 索瑞索制药公司 | Polypeptides |
| KR20220099585A (en) * | 2019-10-25 | 2022-07-13 | 암젠 인크 | Compositions and Methods for Minimizing Protein Loss at Low Protein Concentrations |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| MX2022016069A (en) | 2020-06-19 | 2023-02-02 | Hoffmann La Roche | Antibodies binding to cd3 and cd19. |
| WO2023201291A1 (en) * | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
| US20230406930A1 (en) * | 2022-04-13 | 2023-12-21 | Genentech, Inc. | Pharmaceutical compositions of therapeutic proteins and methods of use |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1995016460A1 (en) * | 1993-12-17 | 1995-06-22 | Mochida Pharmaceutical Co., Ltd. | Composition containing soluble thrombomodulins |
| JP4454571B2 (en) * | 1998-03-06 | 2010-04-21 | 中外製薬株式会社 | Protein-free formulation |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US20050043519A1 (en) | 2001-08-10 | 2005-02-24 | Helen Dooley | Antigen binding domains |
| US20030104996A1 (en) | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
| WO2003032727A1 (en) * | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| KR100913714B1 (en) | 2001-11-08 | 2009-08-24 | 패시트 바이오테크 코포레이션 | Stable liquid pharmaceutical formulation of igg antibodies |
| AR053553A1 (en) | 2005-03-08 | 2007-05-09 | Pharmacia & Upjohn Co Llc | COMPOSITION OF ANTI BODIES ANTI MOLECULA OF CELLULAR ADRESIN MUCOSA (ANTI-MADCAM) |
| US7989665B2 (en) | 2005-04-05 | 2011-08-02 | Firmenich Sa | Hydrogenation of esters with Ru/tetradentate ligands complexes |
| AU2006291005A1 (en) * | 2005-09-12 | 2007-03-22 | Novimmune S.A. | Anti-CD3 antibody formulations |
| WO2012052996A2 (en) | 2010-10-19 | 2012-04-26 | Yeda Research And Development Co. Ltd. | Novel ruthenium complexes and their uses in processes for formation and/or hydrogenation of esters, amides and derivatives thereof |
| US9308257B2 (en) | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| JP2010241718A (en) * | 2009-04-03 | 2010-10-28 | Kyowa Hakko Kirin Co Ltd | Stable aqueous solution preparation of antibody |
| EP2453874A2 (en) * | 2009-07-14 | 2012-05-23 | Biogen Idec MA Inc. | Methods for inhibiting yellow color and peroxide formation in a composition |
| US20120294866A1 (en) | 2010-01-19 | 2012-11-22 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for proteins |
| JP2013534925A (en) | 2010-06-25 | 2013-09-09 | グラクソ グループ リミテッド | Treatment method for patients with immune related diseases |
| KR20140045440A (en) * | 2011-06-30 | 2014-04-16 | 제넨테크, 인크. | Anti-c-met antibody formulations |
| CN105073136A (en) | 2013-03-15 | 2015-11-18 | 葛兰素史克知识产权第二有限公司 | Low concentration antibody formulations |
-
2014
- 2014-03-13 CN CN201480016095.4A patent/CN105073136A/en active Pending
- 2014-03-13 WO PCT/IB2014/059757 patent/WO2014141152A2/en active Application Filing
- 2014-03-13 CA CA2902289A patent/CA2902289A1/en not_active Abandoned
- 2014-03-13 US US14/775,900 patent/US10537638B2/en active Active
- 2014-03-13 TW TW103108897A patent/TW201501724A/en unknown
- 2014-03-13 BR BR112015023498A patent/BR112015023498A2/en not_active Application Discontinuation
- 2014-03-13 RU RU2015137685A patent/RU2015137685A/en not_active Application Discontinuation
- 2014-03-13 AU AU2014229282A patent/AU2014229282B2/en not_active Ceased
- 2014-03-13 EP EP14714396.0A patent/EP2968535A2/en not_active Ceased
- 2014-03-13 JP JP2015562515A patent/JP6541581B2/en active Active
- 2014-03-13 EP EP19198476.4A patent/EP3686217A1/en not_active Withdrawn
- 2014-03-13 KR KR1020157028852A patent/KR20150132332A/en not_active Application Discontinuation
- 2014-03-13 SG SG11201506499YA patent/SG11201506499YA/en unknown
-
2015
- 2015-08-23 IL IL240754A patent/IL240754A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL240754A0 (en) | 2015-10-29 |
| US20160000916A1 (en) | 2016-01-07 |
| CN105073136A (en) | 2015-11-18 |
| EP2968535A2 (en) | 2016-01-20 |
| RU2015137685A (en) | 2017-04-20 |
| CA2902289A1 (en) | 2014-09-18 |
| JP2016513635A (en) | 2016-05-16 |
| US10537638B2 (en) | 2020-01-21 |
| WO2014141152A3 (en) | 2014-12-04 |
| TW201501724A (en) | 2015-01-16 |
| JP6541581B2 (en) | 2019-07-10 |
| KR20150132332A (en) | 2015-11-25 |
| EP3686217A1 (en) | 2020-07-29 |
| AU2014229282A1 (en) | 2015-10-08 |
| BR112015023498A2 (en) | 2017-10-10 |
| WO2014141152A2 (en) | 2014-09-18 |
| RU2015137685A3 (en) | 2018-03-05 |
| AU2014229282B2 (en) | 2017-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202005525B (en) | Antibody formulations | |
| IL269528A (en) | Anti-fcrh5 antibodies | |
| IL240754A0 (en) | Low concentration antibody formulations | |
| IL244712A0 (en) | Anti-pdl1 antibody formulations | |
| HK1223544A1 (en) | Antibody formulations and methods | |
| HK1218549A1 (en) | Novel antibody frameworks | |
| GB201322583D0 (en) | Antibodies | |
| HK1220142A1 (en) | Antibodies | |
| GB201308658D0 (en) | Antibodies | |
| GB201315486D0 (en) | Antibodies | |
| GB201300706D0 (en) | Antibody | |
| IL245488B (en) | Anti-ccl17 antibodies | |
| HK1220366A1 (en) | Protein formulations | |
| GB201318502D0 (en) | Determining nagalase concentration |